SynthesisCancer medicine2026
The Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review.
Synthesis in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic therapies can impact local disease progression in genitourinary malignancies, potentially reducing the necessity for extensive surgery. Understanding these effects is crucial for optimizing treatment approaches in urologic oncology.
methodsThrough PubMed and Scopus databases search up to May 2026, we identified studies focusing on surgical outcomes after systemic therapy in prostate, kidney, testicular, and bladder cancers.
resultsIn prostate cancer (PC), neoadjuvant hormonal therapy improved margin status and organ confinement but did not enhance biochemical-free survival rates. Chemotherapy or immunotherapy provided no clinical benefit. In kidney cancer, tyrosine kinase inhibitors and immune checkpoint inhibitors reduced tumor diameter by 13.5%-35% but did not improve recurrence-free survival. Certain therapeutic combinations decreased vena cava thrombus length, lessening surgical complexity. Post-chemotherapy, testicular cancer specimens revealed viable tumors in 8.3%-25% of cases, teratomas in 18.2%-50.0%, and scar or in situ neoplasms in 31.1%-60.0% of specimens. In muscle-invasive bladder cancer, cisplatin-based chemotherapy resulted in a pathological complete response (pCR) in approximately one-third of patients, and the addition of immunotherapy or antibody-drug conjugates further improved pCR rates. Molecular markers such as circulating tumor DNA and urine tumor DNA are being investigated as potential markers for predicting pCRs.
conclusionsCurrent systemic therapies do not eliminate the need for radical orchiectomy, nephrectomy, or local treatment in PC. The ability to avoid radical surgery in bladder cancer is still investigational. Therefore, attempts to avoid local treatment in patients with genitourinary malignancies should be pursued within the framework of a clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.